Last Trade: 0.135 Bid: 0.1100 Last Size: 100 Ask: 0.1350 Trade Time: 3:55pm Bid x Ask Size: 5000x5000 Change: +0.0140 (+11.57%) Day's Range: 0.12 - 0.14 Prev Close: 0.1210 52wk Range: 0.06 - 0.20 Open: 0.1350 P/E (ttm): N/A Volume: 22,900 EPS (ttm): 0.00

TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. The Company’s vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or ‘accelerant’ to enhance targeted vaccines against infectious diseases. Including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1000 times. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010. The company’s technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular Mechanics and local news papers as well as many respected medical journals including the Journal of Immunology, Nature (Biotechnology), International Journal of Cancer, Cancer Research and PLoS Pathogens among others.

MarketByte LLC has purchased 200,000 shares of Tapimmune with a cost basis of fifteen cents from a non affiliate shareholder. The shares are freely tradeable. This should be construed as a form of compensation and a conflict of interest. The aforementioned shares could be sold at anytime without prior notification.